Mannitol Baxter Healthcare (Mannitol)

Mannitol raises the osmolarity of the extracellular fluid after intravenous administration. The resulting osmotic gradient draws water out of cells and interstitial spaces into the vascular compartment, reducing tissue edema, decreasing pressure in confined spaces such as the skull or eye, and expanding plasma volume to support renal filtration.

The dosage of Mannitol is individualized and determined by the prescribing clinician based on the specific indication, patient weight, renal function, and response to therapy. Healthcare professionals calculate the appropriate infusion rate and total amount according to established clinical guidelines.

Mannitol is classified as pregnancy category unknown, and limited data are available on its use in pregnant or lactating individuals. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mannitol is a widely used osmotic diuretic with a rapid onset of action and predictable osmotic effect. Compared with alternatives such as hypertonic saline, Mannitol provides both volume expansion and osmotic pressure reduction, making it suitable for intracranial pressure management and renal protection, though choice depends on patient-specific factors and clinical judgment.

Mannitol Baxter Healthcare should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Ensure the vial or bag remains in its original packaging until use to maintain sterility and stability.

Mannitol is administered intravenously, typically as an infusion. The solution is diluted in compatible IV fluids and infused over a controlled period, with the rate adjusted according to the clinical indication and patient tolerance. Administration should be performed by qualified healthcare personnel in a monitored setting.

Serious risks include severe hypernatremia, pulmonary edema, anaphylactic reactions, acute renal failure, and profound hypotension. These events require immediate medical attention and may be mitigated by careful patient selection, dose titration, and close monitoring of vital signs and laboratory parameters.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial hemorrhage where increased volume could worsen outcomes, uncontrolled heart failure, and severe renal impairment where osmotic diuresis may be ineffective or harmful. Clinical assessment is essential before initiation.